Fintel studies that on May 26, 2023, HC Wainwright & Co. reiterated protection of Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy suggestion.
Analyst Price Forecast Suggests 184.87% Upside
As of May 11, 2023, the common one-year worth goal for Bolt Biotherapeutics is 5.27. The forecasts vary from a low of three.03 to a excessive of $8.40. The common worth goal represents a rise of 184.87% from its newest reported closing worth of 1.85.
See our leaderboard of firms with the most important worth goal upside.
The projected annual income for Bolt Biotherapeutics is 5MM, a lower of 25.47%. The projected annual non-GAAP EPS is -2.02.
What is the Fund Sentiment?
There are 66 funds or establishments reporting positions in Bolt Biotherapeutics. This is a lower of 4 proprietor(s) or 5.71% within the final quarter. Average portfolio weight of all funds devoted to BOLT is 0.08%, a rise of 25.64%. Total shares owned by establishments elevated within the final three months by 12.59% to 23,417K shares.
What are Other Shareholders Doing?
Vivo Capital holds 3,871K shares representing 10.24% possession of the corporate. No change within the final quarter.
Citadel Advisors holds 2,838K shares representing 7.51% possession of the corporate. In it is prior submitting, the agency reported proudly owning 2,752K shares, representing a rise of three.04%. The agency elevated its portfolio allocation in BOLT by 3.82% over the past quarter.
Sofinnova Investments holds 2,754K shares representing 7.28% possession of the corporate. No change within the final quarter.
Pivotal bioVenture Partners Investment Advisor holds 1,891K shares representing 5.00% possession of the corporate. No change within the final quarter.
Tang Capital Management holds 1,628K shares representing 4.30% possession of the corporate. In it is prior submitting, the agency reported proudly owning 400K shares, representing a rise of 75.42%. The agency elevated its portfolio allocation in BOLT by 346.20% over the past quarter.
Bolt Biotherapeutics Background Information
(This description is supplied by the corporate.)
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology firm growing tumor-targeted therapies that leverage the facility of the innate and adaptive immune methods. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) strategy combines an antibody that targets a tumor antigen with an immune stimulant that triggers an innate and adaptive immune response within the tumor microenvironment. These systemically-delivered Boltbody ISACs are designed to focus on tumor cells for elimination by myeloid cells, that are then activated and recruit the adaptive immune system within the anti-tumor response. This results in the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to certainly one of Bolt’s proprietary TLR7/8 agonists for the remedy of sufferers with HER2-expressing stable tumors. Bolt can be advancing BDC-2034, a Boltbody ISAC focusing on CEA, and a pipeline of different immuno-oncology merchandise.
Key filings for this firm:
This story initially appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.